Ajax Therapeutics

Drug Discovery · New York, NY · Founded 2019 · Privately Held (backing)

Developer of targeted therapy drugs designed for the treatment of hematologic cancers. Ajax Therapeutics is based in New York, NY and was founded in 2019. Its last known valuation is $193 million. It has raised $143 million across 3 recorded rounds; the latest was a $95 million Series C in May 2024.

Last price · $/share
—
Implied valuation
$192.5M
Total raised
$143.0M
Last round
Later Stage VC (Series C)
May 2024
No prints on record

No secondary trades in Ajax Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Ajax Therapeutics with a free account
  • ·The complete investor list: 11 names
  • ·Watch Ajax Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Where Ajax Therapeutics prices come from

Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Ajax Therapeutics stock.